BeiGene Ltd ADR buy melinda
Start price
12.11.18
/
50%
€109.65
Target price
28.11.18
€144.32
Performance (%)
19.77%
End price
28.11.18
€131.32
Summary
This prediction ended on 28.11.18 with a price of €131.32. The prediction had a final performance of 19.77%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| BeiGene Ltd ADR | 2.308% | 2.308% | 55.556% | 27.885% |
| iShares Core DAX® | 0.765% | 4.791% | 21.634% | 71.886% |
| iShares Nasdaq 100 | 1.418% | 3.133% | 5.422% | 113.046% |
| iShares Nikkei 225® | 0.658% | 0.972% | 15.333% | 47.267% |
| iShares S&P 500 | 1.310% | 2.279% | 3.125% | 68.687% |
Comments by melinda for this prediction
In the thread Beigene Ltd ADR diskutieren
SecteurRecherche biotechnologique et médicale Agenda 15/11 Présentation
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer.
It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).
The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
Nombre d'employés : 900 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for BeiGene Ltd ADR
BeiGene Ltd ADR
Start price
Target price
Perf. (%)
€124.64
02.04.19
02.04.19
€250.00
04.11.21
04.11.21
158.35%
05.11.21
05.11.21
